US-India relations stall over pharma IP squabble

Published: 8-Jun-2015
Regulatory Patient Experience

IP protection for international pharmaceutical companies in India remains an unresolved issue, as India battles for affordable medicines and the US argues that better patent protection must be forthcoming. The potential of this huge market hangs in the balance as discussions continue

You need to be a subscriber to read this article.
Click here to find out more.

American pharmaceutical industry officials and trade groups remain cautiously optimistic that intellectual property (IP) negotiations with India can be resolved to the benefit of both nations’ medicine sectors. For now, however, India remains on a so-called ‘priority watch list’ of nations the US is urging to address key IP protection concerns.

The latest congressionally mandated ‘301 Report’, released in April, places India alongside 12 other US trading partner nations, including China, Indonesia, Pakistan and Russia, that ‘present the most significant concerns this year regarding insufficient IP protection or enforcement or actions that otherwise limited market access for persons relying on intellectual property protection’.

India remains on the list for 2015, the report says, but ‘with the full expectation that the new channels for engagement created in the past year will bring about substantive and measurable improvements in India’s intellectual property regime (IPR) for the benefit of a broad range of innovative and creative industries.’

Not yet a Subscriber?

This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.

Subscribe now Already a subscriber? Sign in here.
  • Companies:
  • Gilead Sciences
  • Bayer
  • Novartis
See more

You may also like

Regulatory

Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy

Read more
The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations

Trending Articles

  1. Accelerating and enhancing toxicology assessments Infographic guides users through ToxHQ’s speedy assessment features
  2. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  3. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  4. You need to be a subscriber to read this article.
    Click here to find out more.
    Why quality control should be intimately combined with sterile product development, manufacturing and the overall product supply chain With sponsor companies increasingly needing to create and launch differentiated, stable, usable and safe injectable treatments for patients, experts at ten23 health are keen to promote the importance of integrating development and/or manufacturing with quality control services
  5. The right validation model: practical considerations and applications It is widely accepted that validation in the life sciences industry follows a lifecycle model (1,2). What is not always clear is the specific model — or models — to follow and how to navigate through them in the real world. Hurdles to overcome include the specific deliverables that make up that model and how they change during the various interactions along the validation journey

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy

The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
Regulatory

Novartis obtains FDA approval for CML drug, Scemblix

The TKI's approval is an important step forward for oncology patients with newly diagnosed chronic myeloid leukaemia, and was based on the results of the Phase III ASC4FIRST trial
Regulatory

Novartis' Kisqali plus ET bags FDA approval for HR+/HER2- breast cancer

The decision comes off the back of the Phase III NATALEE clinical trial, which diminished the risk of disease recurrence by 25.1%
Regulatory

Novartis' Fabhalta bags FDA accelerated approval for Berger's disease

Fabhalta, or iptacopan, is a complement inhibitor designed to reduce proteinuria in primary IgA nephropathy, a chronic kidney disease
Ingredients

Therapeutic: tislelizumab for oncology

With three main subtypes (adenocarcinoma, squamous cell carcinoma and large cell), non-small cell lung cancer is the predominant form of lung cancer
Ingredients

Therapeutic: leniolisib for APDS

APDS or activated phosphoinositide 3-kinase delta (PI3K∂) syndrome is an ultra-rare primary immunodeficiency disease
Ingredients

Therapeutics: osilodrostat for Cushing’s disease

Cushing’s disease is a rare condition in which the adrenal glands overproduce the hormone cortisol
Subscribe now